A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer

Sponsor
Biotroy Therapeutics
Study ID
NCT07110363
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • BT02 — DRUG
    monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Study Details

The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.

Key Dates

First listed
Aug 7, 2025
Start date
Aug 31, 2025
Status verified
Jul 2025
Primary completion
Mar 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
58 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: dose escalation and expansion

Primary Outcome Measure

Adverse events [ Time Frame: through study completion, an average of 2 years ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies